Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) formed by aggregates of hyperphosphorylated tau proteins. It presents a formidable global health challenge, prompting the exploration of innovative therapeutic strategies. This review aims to provide a thorough discussion of astrocytes and microglia to examine whether they are overall beneficial or detrimental for AD on the global level. Based on this, this review describes the treatment solutions that are likely to entail the manipulation of glial cells to reduce inflammation, opting to boost clearance of toxic proteins, thus stabilizing the effects of AD. These glial entities, inherent to the central nervous system, extend their functions beyond structural support, actively engaging in various physiological and pathological processes associated with AD. Both astroglia and microglia contribute significantly to the neuroinflammatory response observed in AD. Reactive astrocytes release inflammatory mediators, while activated microglia release cytokines, chemokines, and reactive oxygen species, collectively assisting a chronic state of neuroinflammation. Additionally, astrocytes partake in the clearance of Aβ, while microglia play a pivotal role in phagocytosing Aβ plaques. In AD, ongoing inflammation may cause a buildup of Aβ, which causes problems with the functions of astroglia and microglia and also worsens these issues with communication between neurons, a key factor in cognitive decline. In addition, there are tremendous opportunities to identify new biomarkers specific to glial disorders, genomic and epigenomic approaches for the selection of patients, using multimodal imaging techniques, and the application of machine learning algorithms in the future for personalized glial-targeted therapies.
KnopmanDSAmievaHPetersenRC, et al.Alzheimer disease. Nat Rev Dis Primers2021; 7: 33.
2.
MonteiroARBarbosaDJRemiãoF, et al.Alzheimer's disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol2023; 211: 115522.
3.
AlzheimerAStelzmannRASchnitzleinHN, et al.An English translation of Alzheimer's 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”. Clin Anat1995; 8: 429–431.
4.
DrouinEDrouinG. The first report of Alzheimer's disease. Lancet Neurol2017; 16: 687.
LambertJ-CRamirezAGrenier-BoleyB, et al.Step by step: towards a better understanding of the genetic architecture of Alzheimer’s disease. Mol Psychiatry2023; 28: 2716–2727.
7.
HampelHHardyJBlennowK, et al.The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry2021; 26: 5481–5503.
8.
LiuC-CZhaoNFuY, et al.Apoe4 accelerates early seeding of amyloid pathology. Neuron2017; 96: 1024–1032.e1023.
9.
SinhaSAndersonJPBarbourR, et al.Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature1999; 402: 537–540.
10.
KarvandiMSSheikhzadeh HesariFArefAR, et al.The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: the role of ER stress, oxidative stress, and neuroinflammation. Front Cell Neurosci2023; 17: 1105247.
11.
OnoKWatanabe-NakayamaT. Aggregation and structure of amyloid β-protein. Neurochem Int2021; 151: 105208.
12.
DidonnaA. Tau at the interface between neurodegeneration and neuroinflammation. Genes Immun2020; 21: 288–300.
13.
SharoarMGHuXMaX-M, et al.Sequential formation of different layers of dystrophic neurites in Alzheimer’s brains. Mol Psychiatry2019; 24: 1369–1382.
14.
RawatPSeharUBishtJ, et al.Phosphorylated tau in Alzheimer's disease and other tauopathies. Int J Mol Sci2022; 23: 12841.
15.
TziorasMMcGeachanRIDurrantCS, et al.Synaptic degeneration in Alzheimer disease. Nat Rev Neurol2023; 19: 19–38.
16.
KongWLPengYYPengBW. Modulation of neuroinflammation: role and therapeutic potential of TRPV1 in the neuro-immune axis. Brain Behav Immun2017; 64: 354–366.
17.
ZhangGWangZHuH, et al.Microglia in Alzheimer’s disease: a target for therapeutic intervention. Front Cell Neurosci2021; 15: 749587.
18.
ColangeloAMAlberghinaLPapaM. Astrogliosis as a therapeutic target for neurodegenerative diseases. Neurosci Lett2014; 565: 59–64.
19.
MatejukARansohoffRM. Crosstalk between astrocytes and microglia: an overview. Front Immunol2020; 11: 1416.
20.
GarlandEFHartnellIJBocheD. Microglia and astrocyte function and communication: what do we know in humans?Front Neurosci2022; 16: 824888.
21.
JungY-JChungW-S. Phagocytic roles of glial cells in healthy and diseased brains. Biomol Ther (Seoul)2018; 26: 350.
22.
BeardELengacherSDiasS, et al.Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives. Front Physiol2021; 12: 825816.
23.
ChungWSAllenNJErogluC. Astrocytes control synapse formation, function, and elimination. Cold Spring Harb Perspect Biol2015; 7: a020370.
24.
HaruwakaKYingYLiangY, et al.Microglia enhance post-anesthesia neuronal activity by shielding inhibitory synapses. Nat Neurosci2024; 27: 449–461.
25.
HuYTaoW. Current perspectives on microglia-neuron communication in the central nervous system: direct and indirect modes of interaction. J Adv Res2024; 66: 251–265.
26.
Augusto-OliveiraMArrifanoGPLopes-AraújoA, et al.What do microglia really do in healthy adult brain?Cells2019; 8: 1293.
27.
ArakiTIkegayaYKoyamaR. The effects of microglia- and astrocyte-derived factors on neurogenesis in health and disease. Eur J Neurosci2021; 54: 5880–5901.
28.
ShieldsDCHaqueABanikNL. Neuroinflammatory responses of microglia in central nervous system trauma. J Cereb Blood Flow Metab2020; 40: S25–S33.
29.
Gomes-LealW. Microglial physiopathology: how to explain the dual role of microglia after acute neural disorders?Brain Behav2012; 2: 345–356.
30.
ParkhurstCNYangGNinanI, et al.Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell2013; 155: 1596–1609.
31.
ShaoFWangXWuH, et al.Microglia and neuroinflammation: crucial pathological mechanisms in traumatic brain injury-induced neurodegeneration. Front Aging Neurosci2022; 14: 825086.
32.
ZhaoSUmpierreADWuL-J. Tuning neural circuits and behaviors by microglia in the adult brain. Trends Neurosci2024; 47: 181–194.
33.
KettenmannHHanischUKNodaM, et al.Physiology of microglia. Physiol Rev2011; 91: 461–553.
34.
CornellJSalinasSHuangHY, et al.Microglia regulation of synaptic plasticity and learning and memory. Neural Regen Res2022; 17: 705–716.
35.
AndohMKoyamaR. Microglia and GABA: diverse functions of microglia beyond GABA-receiving cells. Neurosci Res2023; 187: 52–57.
36.
PascualOBen AchourSRostaingP, et al.Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A2012; 109: E197–E205.
37.
Colucci-D'AmatoLSperanzaLVolpicelliF. Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci2020; 21: 7777.
38.
BasilicoBFerrucciLKhanA, et al.What microglia depletion approaches tell us about the role of microglia on synaptic function and behavior. Front Cell Neurosci2022; 16: 1022431.
39.
CostaJMartinsSFerreiraPA, et al.The old guard: age-related changes in microglia and their consequences. Mech Ageing Dev2021; 197: 111512.
40.
TremblayMÈZettelMLIsonJR, et al.Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices. Glia2012; 60: 541–558.
41.
WangZLeiHZhengM, et al.Meta-analysis of the association between Alzheimer disease and variants in GAB2, PICALM, and SORL1. Mol Neurobiol2016; 53: 6501–6510.
42.
LiY-QTanM-SWangH-F, et al.Common variant in PTK2B is associated with late-onset Alzheimer’s disease: a replication study and meta-analyses. Neurosci Lett2016; 621: 83–87.
43.
ZhangYSloanSAClarkeLE, et al.Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron2016; 89: 37–53.
44.
SemyanovAVerkhratskyA. Astrocytic processes: from tripartite synapses to the active milieu. Trends Neurosci2021; 44: 781–792.
45.
KumarAFontanaICNordbergA. Reactive astrogliosis: a friend or foe in the pathogenesis of Alzheimer's disease. J Neurochem2023; 164: 309–324.
46.
ParpuraVHenekaMTMontanaV, et al.Glial cells in (patho) physiology. J Neurochem2012; 121: 4–27.
47.
SofroniewMVVintersHV. Astrocytes: biology and pathology. Acta Neuropathol2010; 119: 7–35.
48.
ChapuisJFlaigAGrenier-BoleyB, et al.Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol2017; 133: 955–966.
49.
WangZ-XWangH-FTanL, et al.Effects of HLA-DRB1/DQB1 genetic variants on neuroimaging in healthy, mild cognitive impairment, and Alzheimer’s disease cohorts. Mol Neurobiol2017; 54: 3181–3188.
50.
WesPDSayedFABardF, et al.Targeting microglia for the treatment of Alzheimer's disease. Glia2016; 64: 1710–1732.
51.
JingHZhuJ-XWangH-F, et al.INPP5D Rs35349669 polymorphism with late-onset Alzheimer's disease: a replication study and meta-analysis. Oncotarget2016; 7: 69225.
52.
LewcockJWSchlepckowKDi PaoloG, et al.Emerging microglia biology defines novel therapeutic approaches for Alzheimer’s disease. Neuron2020; 108: 801–821.
53.
AlthafarZM. Targeting microglia in Alzheimer’s disease: from molecular mechanisms to potential therapeutic targets for small molecules. Molecules2022; 27: 4124.
54.
ColonnaMButovskyO. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol2017; 35: 441–468.
55.
XuNCaoRChenSY, et al.Structural and functional reorganization of inhibitory synapses by activity-dependent cleavage of neuroligin-2. Proc Natl Acad Sci U S A2024; 121: e2314541121.
56.
AuNPBMaCHE. Recent advances in the study of bipolar/rod-shaped microglia and their roles in neurodegeneration. Front Aging Neurosci2017; 9: 128.
57.
Vidal-ItriagoARadfordRAWAramidehJA, et al.Microglia morphophysiological diversity and its implications for the CNS. Front Immunol2022; 13: 997786.
58.
PlescherMSeifertGHansenJN, et al.Plaque-dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer's disease mouse model. Glia2018; 66: 1464–1480.
59.
Sanchez-MejiasENavarroVJimenezS, et al.Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration. Acta Neuropathol2016; 132: 897–916.
60.
NavarroVSanchez-MejiasEJimenezS, et al.Microglia in Alzheimer’s disease: activated, dysfunctional or degenerative. Front Aging Neurosci2018; 10: 140.
61.
TischerJKruegerMMuellerW, et al.Inhomogeneous distribution of iba-1 characterizes microglial pathology in Alzheimer's disease. Glia2016; 64: 1562–1572.
62.
YinZRajDSaiepourN, et al.Immune hyperreactivity of aβ plaque-associated microglia in Alzheimer's disease. Neurobiol Aging2017; 55: 115–122.
63.
NguyenHMGrössingerEMHoriuchiM, et al.Differential Kv1. 3, KCa3. 1, and Kir2. 1 expression in “classically” and “alternatively” activated microglia. Glia2017; 65: 106–121.
64.
Frank-CannonTCAltoLTMcAlpineFE, et al.Does neuroinflammation fan the flame in neurodegenerative diseases?Mol Neurodegener2009; 4: 47.
65.
JhaMKLeeW-HSukK. Functional polarization of neuroglia: implications in neuroinflammation and neurological disorders. Biochem Pharmacol2016; 103: 1–16.
66.
TangYLeW. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol2016; 53: 1181–1194.
67.
SongGJNamYJoM, et al.A novel small-molecule agonist of PPAR-γ potentiates an anti-inflammatory M2 glial phenotype. Neuropharmacology2016; 109: 159–169.
68.
RothsteinJDDykes-HobergMPardoCA, et al.Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron1996; 16: 675–686.
69.
NiYParpuraV. Dual regulation of Ca2+-dependent glutamate release from astrocytes: vesicular glutamate transporters and cytosolic glutamate levels. Glia2009; 57: 1296–1305.
70.
LewerenzJKleinMMethnerA. Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc–protects from oxidative glutamate toxicity. J Neurochem2006; 98: 916–925.
OkadaSNakamuraMKatohH, et al.Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med2006; 12: 829–834.
73.
VerkhratskyARodríguezJJSteardoL. Astrogliopathology: a central element of neuropsychiatric diseases?Neuroscientist2014; 20: 576–588.
74.
LiMPisalyaputKGalvanM, et al.Macrophage colony stimulatory factor and interferon-γ trigger distinct mechanisms for augmentation of β-amyloid-induced microglia-mediated neurotoxicity. J Neurochem2004; 91: 623–633.
75.
WildburgerNCGyngardFGuillermierC, et al.Amyloid-β plaques in clinical Alzheimer’s disease brain incorporate stable isotope tracer in vivo and exhibit nanoscale heterogeneity. Front Neurol2018; 9: 169.
76.
TakeuchiHJinSWangJ, et al.Tumor necrosis factor-α induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem2006; 281: 21362–21368.
77.
BordjiKBecerril-OrtegaJNicoleO, et al.Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production. J Neurosci2010; 30: 15927–15942.
78.
WilkinsonKEl KhouryJ. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. Int J Alzheimers Dis2012; 2012: 489456.
79.
KhouryEToftJHickmanM, , et al.Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med2007; 13: 432–438.
80.
WeinerHLFrenkelD. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol2006; 6: 404–416.
81.
JaworskiTLechatBDemedtsD, et al.Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration. Am J Pathol2011; 179: 2001–2015.
82.
AkbaralyNTHininger-FavierICarriereI, et al.Plasma selenium over time and cognitive decline in the elderly. Epidemiology2007; 18: 52–58.
83.
SyMKitazawaMMedeirosR, et al.Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol2011; 178: 2811–2822.
84.
ZhangYZhaoYZhangJ, et al.Mechanisms of NLRP3 inflammasome activation: its role in the treatment of Alzheimer’s disease. Neurochem Res2020; 45: 2560–2572.
85.
SeveriniCBarbatoCCertoD, et al.Alzheimer’s disease: new concepts on the role of autoimmunity and NLRP3 inflammasome in the pathogenesis of the disease. Curr Neuropharmacol2021; 19: 498–512.
86.
TarkowskiEAndreasenNTarkowskiA, et al.Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry2003; 74: 1200–1205.
87.
WrightALZinnRHohensinnB, et al.Neuroinflammation and neuronal loss precede aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One2013; 8: e59586.
88.
NgATamWWZhangMW, et al.IL-1β, IL-6, TNF-α and CRP in elderly patients with depression or Alzheimer’s disease: systematic review and meta-analysis. Sci Rep2018; 8: 12050.
89.
GustinAKirchmeyerMKoncinaE, et al.NLRP3 Inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. PLoS One2015; 10: e0130624.
90.
SaresellaMLa RosaFPianconeF, et al.The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease. Mol Neurodegener2016; 11: 23.
91.
HalleAHornungVPetzoldGC, et al.The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol2008; 9: 857–865.
92.
StreitWJMrakREGriffinWST. Microglia and neuroinflammation: a pathological perspective. J Neuroinflamm2004; 1: 14.
93.
GraeberMBLiWRodriguezML. Role of microglia in CNS inflammation. FEBS Lett2011; 585: 3798–3805.
94.
RosczykHSparkmanNJohnsonR. Neuroinflammation and cognitive function in aged mice following minor surgery. Exp Gerontol2008; 43: 840–846.
95.
PonomarevEDShriverLPMareszK, et al.Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res2005; 81: 374–389.
96.
RockRBGekkerGHuS, et al.Role of microglia in central nervous system infections. Clin Microbiol Rev2004; 17: 942–964.
97.
KamphuisWMamberCMoetonM, et al.GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. 2012.
98.
FraserHBMosesAMSchadtEE. Evidence for widespread adaptive evolution of gene expression in budding yeast. Proc Natl Acad Sci U S A2010; 107: 2977–2982.
99.
InoueKTsudaM. Purinergic systems, neuropathic pain and the role of microglia. Exp Neurol2012; 234: 293–301.
100.
PerryVHTeelingJ. Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol2013; 35: 601–612.
101.
SelkoeDJ. Alzheimer's disease is a synaptic failure. Science2002; 298: 789–791.
102.
Di FilippoMTozziACostaC, et al.Plasticity and repair in the post-ischemic brain. Neuropharmacology2008; 55: 353–362.
103.
Von BernhardiREugenín-von BernhardiLEugenínJ. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci2015; 7: 124.
104.
CagninABrooksDJKennedyAM, et al.In-vivo measurement of activated microglia in dementia. Lancet2001; 358: 461–467.
105.
SUKde VellisJ. Microglia in health and disease. J Neurosci Res2005; 81: 302–313.
KitazawaMChengDTsukamotoMR, et al.Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer’s disease model. J Immunol2011; 187: 6539–6549.
108.
EspositoGScuderiCLuJ, et al.S100b induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med2008; 12: 914–927.
109.
SpoorenAMestdaghPRondouP, et al.IL-1β potently stabilizes IL-6 mRNA in human astrocytes. Biochem Pharmacol2011; 81: 1004–1015.
110.
LiddelowSAGuttenplanKAClarkeLE, et al.Neurotoxic reactive astrocytes are induced by activated microglia. Nature2017; 541: 481–487.
111.
ZamanianJLXuLFooLC, et al.Genomic analysis of reactive astrogliosis. J Neurosci2012; 32: 6391–6410.
112.
KamatPKRaiSNathC. Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer's disease pathology. Neurotoxicology2013; 37: 163–172.
113.
YangXYangYFuZ, et al.Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol2011; 25: 1118–1125.
114.
BhatRXueYBergS, et al.Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem2003; 278: 45937–45945.
115.
MartinezAAlonsoMCastroA, et al.First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem2002; 45: 1292–1299.
116.
PickhardtMBiernatJKhlistunovaI, et al.N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr Alzheimer Res2007; 4: 397–402.
117.
ZhangBCarrollJTrojanowskiJQ, et al.The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci2012; 32: 3601–3611.
118.
MinS-WChenXTracyTE, et al.Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med2015; 21: 1154–1162.
119.
KimJEltoraiAEJiangH, et al.Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. J Exp Med2012; 209: 2149–2156.
120.
ChengQDanaoJTalrejaS, et al.TREM2-activating Antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem2R47H on murine myeloid cell function. J Biol Chem2018; 293: 12620–12633.
121.
ZhangLFangYLianY, et al.Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer's disease induced by aβ1–42. PLoS One2015; 10: e0122415.
122.
ChiozziPSartiACSanzJM, et al.Amyloid β-dependent mitochondrial toxicity in mouse microglia requires P2X7 receptor expression and is prevented by nimodipine. Sci Rep2019; 9: 6475.
123.
SatoTHanyuHHiraoK, et al.Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging2011; 32: 1626–1633.
124.
SchlepckowKMonroeKMKleinbergerG, et al.Enhancing protective microglial activities with a dual function TREM 2 antibody to the stalk region. EMBO Mol Med2020; 12: e11227.
125.
MuffatJLiYYuanB, et al.Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med2016; 22: 1358–1367.
126.
RojoRRaperAOzdemirDD, et al.Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. Nat Commun2019; 10: 3215.
127.
ChiareliRACarvalhoGAMarquesBL, et al.The role of astrocytes in the neurorepair process. Front Cell Dev Biol2021; 9: 665795.
128.
PasqualettiPBonominiCDal FornoG, et al.A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin Exp Res2009; 21: 102–110.
129.
RogersJKirbyLHempelmanS, et al.Clinical trial of indomethacin in Alzheimer's disease. Neurology1993; 43: 1609–1609.
130.
MancusoRVan Den DaeleJFattorelliN, et al.Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat Neurosci2019; 22: 2111–2116.
131.
LeeI-SJungKKimI-S, et al.Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. Mol Neurodegener2015; 10: 38.
132.
FerrerI. Diversity of astroglial responses across human neurodegenerative disorders and brain aging. Brain Pathol2017; 27: 645–674.
GaoCJiangJTanY, et al.Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther2023; 8: 359.
135.
FrostGRLiY-M. The role of astrocytes in amyloid production and Alzheimer's disease. Open Biol2017; 7: 170228.
136.
GriffinWST. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation2008; 5: 3.
137.
HuangWYLaiYLLiuKH, et al.TNFα-mediated necroptosis in brain endothelial cells as a potential mechanism of increased seizure susceptibility in mice following systemic inflammation. J Neuroinflammation2022; 19: 29.
138.
WangSPanYZhangC, et al.Transcriptome analysis reveals dynamic microglial-induced A1 astrocyte reactivity via C3/C3aR/NF-κB signaling after ischemic stroke. Mol Neurobiol2024; 61: 10246–10270.
139.
KalinderiKPapaliagkasVFidaniL. GLP-1 receptor agonists: a new treatment in Parkinson's disease. Int J Mol Sci2024; 25: 3812.
140.
LohrC. Role of P2Y receptors in astrocyte physiology and pathophysiology. Neuropharmacology2023; 223: 109311.
141.
GoetzlEJSchwartzJBAbnerEL, et al.High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol2018; 83: 544–552.
142.
DinizLPTortelliVMatiasI, et al.Astrocyte transforming growth factor beta 1 protects synapses against aβ oligomers in Alzheimer's disease model. J Neurosci2017; 37: 6797–6809.
143.
KlyucherevTOOlszewskiPShalimovaAA, et al.Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener2022; 11: 25.
144.
ParkYJYooSAKimM, et al.The role of calcium-calcineurin-NFAT signaling pathway in health and autoimmune diseases. Front Immunol2020; 11: 195.
145.
BrodSA. Anti-inflammatory agents: an approach to prevent cognitive decline in Alzheimer's disease. J Alzheimers Dis2022; 85: 457–472.
146.
Al-AzayzihAAl-AzzamSIAlzoubiKH, et al.Nonsteroidal anti-inflammatory drugs utilization patterns and risk of adverse events due to drug-drug interactions among elderly patients: a study from Jordan. Saudi Pharm J2020; 28: 504–508.
147.
RavichandranRMohanSKSukumaranSK, et al.An open label randomized clinical trial of indomethacin for mild and moderate hospitalised COVID-19 patients. Sci Rep2022; 12: 6413.
148.
KrauseDLMüllerN. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int J Alzheimers Dis2010; 2010: 732806.
149.
MöllerTBardFBhattacharyaA, et al.Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor. Glia2016; 64: 1788–1794.
150.
WoodH. Minocycline reduces microglial activation but increases neurodegeneration after TBI. Nat Rev Neurol2018; 14: 127–127.
151.
KwonHSKohSH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener2020; 9: 42.
152.
SpangenbergESeversonPLHohsfieldLA, et al.Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat Commun2019; 10: 3758.
153.
CasaliBTMacPhersonKPReed-GeaghanEG, et al.Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis2020; 142: 104956.
154.
DouvarasPSunBWangM, et al.Directed differentiation of human pluripotent stem cells to microglia. Stem Cell Rep2017; 8: 1516–1524.
155.
HaenselerWSansomSNBuchrieserJ, et al.A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. Stem Cell Rep2017; 8: 1727–1742.
156.
KimJHaSShinK, et al.Neural stem cell transplantation at critical period improves learning and memory through restoring synaptic impairment in Alzheimer’s disease mouse model. Cell Death Dis2015; 6: e1789–e1789.
157.
SosnaJPhilippSAlbayR, et al.Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease. Mol Neurodegener2018; 13: 11.
158.
AsaiHIkezuSTsunodaS, et al.Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci2015; 18: 1584–1593.
159.
BruttgerJKarramKWörtgeS, et al.Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity2015; 43: 92–106.
160.
RuganzuJBZhengQWuX, et al.TREM2 Overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway. Exp Neurol2021; 336: 113506.
161.
WangSMustafaMYuedeCM, et al.Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med2020; 217: e20200785.
162.
ZhaoL. CD33 In Alzheimer’s disease–biology, pathogenesis, and therapeutics: a mini-review. Gerontology2019; 65: 323–331.
163.
MilesLAHermansSJCrespiGA, et al.Small molecule binding to Alzheimer risk factor CD33 promotes aβ phagocytosis. Iscience2019; 19: 110–118.
164.
McLarnonJGRyuJKWalkerDG, et al.Upregulated expression of purinergic P2X7 receptor in Alzheimer disease and amyloid-β peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol2006; 65: 1090–1097.
165.
LimGPYangFChuT, et al.Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci2000; 20: 5709–5714.
166.
HenekaMTSastreMDumitrescu-OzimekL, et al.Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice. Brain2005; 128: 1442–1453.
167.
WilkinsonBLCramerPEVarvelNH, et al.Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol Aging2012; 33: 197.e121–197.e132.
168.
ThawkarBSKaurG. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease. J Neuroimmunol2019; 326: 62–74.
169.
DempseyCAraizARBrysonK, et al.Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun2017; 61: 306–316.
170.
YinJZhaoFChojnackiJE, et al.NLRP3 Inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer’s disease. Mol Neurobiol2018; 55: 1977–1987.
171.
LučiūnaitėAMcManusRMJankunecM, et al.Soluble Aβ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. J Neurochem2020; 155: 650–661.
172.
GarcezMLMinaFBellettini-SantosT, et al.The involvement of NLRP3 on the effects of minocycline in an AD-like pathology induced by β-amyloid oligomers administered to mice. Mol Neurobiol2019; 56: 2606–2617.
173.
LinLLiCZhangD, et al.Synergic effects of berberine and curcumin on improving cognitive function in an Alzheimer’s disease mouse model. Neurochem Res2020; 45: 1130–1141.
174.
YiannopoulouKGAnastasiouAIZachariouV, et al.Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research. Biomedicines2019; 7: 97.
175.
SinghNBhattacharjeeAKumarP, et al.Targeting multiple disease hallmarks using a synergistic disease-modifying drug combination ameliorates osteoarthritis via inhibition of senescence and inflammation. Life Sci2023; 334: 122212.
176.
ChouT-CTalalayP. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul1984; 22: 27–55.
177.
YangKBaiHOuyangQ, et al.Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol2008; 4: 228.
